OmniAb, Inc. – NASDAQ:OABI
OmniAb stock price today
$2.02
-1.56
-43.73%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
OmniAb stock price monthly change
-19.87%
month
OmniAb stock price quarterly change
-19.87%
quarter
OmniAb stock price yearly change
-41.81%
year
OmniAb key metrics
Market Cap | 418.70M |
Enterprise value | N/A |
P/E | -14.74 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 35.79 |
Price/Book | 2.01 |
PEG ratio | 0.27 |
EPS | -0.64 |
Revenue | 21.04M |
EBITDA | -66.81M |
Income | -63.48M |
Revenue Q/Q | -77.53% |
Revenue Y/Y | -68.29% |
Profit margin | -147.85% |
Oper. margin | -181.56% |
Gross margin | 0% |
EBIT margin | -181.56% |
EBITDA margin | -317.49% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOmniAb stock price history
OmniAb stock forecast
OmniAb financial statements
| Jun 2023 | 6.94M | -14.72M | -212.04% |
|---|---|---|---|
| Sep 2023 | 5.47M | -15.73M | -287.35% |
| Dec 2023 | 4.82M | -14.05M | -291.44% |
| Mar 2024 | 3.80M | -18.96M | -498.84% |
| Dec 2023 | 4.82M | -14.05M | -291.44% |
|---|---|---|---|
| Mar 2024 | 3.80M | -18.96M | -498.84% |
| Oct 2025 | 12.80M | -11.41M | -89.15% |
| Dec 2025 | 18.34M | -7.38M | -40.27% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.14 | -0.16 |
|---|---|---|
| 2024-03-20 | -0.17 | -0.14 |
| 2024-05-09 | -0.17 | -0.19 |
| Jun 2023 | 405239000 | 71.43M | 17.63% |
|---|---|---|---|
| Sep 2023 | 391708000 | 67.15M | 17.15% |
| Dec 2023 | 401985000 | 87.4M | 21.74% |
| Mar 2024 | 352556000 | 51.16M | 14.51% |
| Jun 2023 | -10.02M | 7.78M | 478K |
|---|---|---|---|
| Sep 2023 | -6.19M | 6.28M | 171K |
| Dec 2023 | -9.12M | 4.73M | -496K |
| Mar 2024 | -17.03M | 19.93M | -203K |
OmniAb alternative data
| Aug 2023 | 95 |
|---|---|
| Sep 2023 | 95 |
| Oct 2023 | 95 |
| Nov 2023 | 95 |
| Dec 2023 | 95 |
| Jan 2024 | 95 |
| Feb 2024 | 95 |
| Mar 2024 | 106 |
| Apr 2024 | 106 |
| May 2024 | 106 |
| Jun 2024 | 106 |
| Jul 2024 | 106 |
OmniAb other data
40.84%
-37.99%
of OABI is owned by hedge funds
90
-55
34.84M
-30.27M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 225000 | 0 |
| Apr 2024 | 0 | 25757 |
| May 2024 | 240000 | 0 |
| Dec 2024 | 0 | 45527 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BERKMAN CHARLES S officer: Chief Le.. | Common Stock | 8,022 | $4.13 | $33,131 | ||
Sale | GUSTAFSON KURT A officer: Executiv.. | Common Stock | 23,871 | $4.13 | $98,587 | ||
Sale | FOEHR MATTHEW W director, officer.. | Common Stock | 13,634 | $4.13 | $56,308 | ||
Option | BERKMAN CHARLES S officer: Chief Le.. | Common Stock | 15,621 | N/A | N/A | ||
Option | BERKMAN CHARLES S officer: Chief Le.. | Restricted Stock Units | 15,621 | N/A | N/A | ||
Option | FOEHR MATTHEW W director, officer.. | Common Stock | 68,360 | $3.75 | $256,350 | ||
Option | FOEHR MATTHEW W director, officer.. | Common Stock | 31,074 | $3.68 | $114,352 | ||
Option | FOEHR MATTHEW W director, officer.. | Stock Option (right to buy) | 68,360 | $3.75 | $256,350 | ||
Option | FOEHR MATTHEW W director, officer.. | Stock Option (right to buy) | 31,074 | $3.68 | $114,352 | ||
Option | BERTOZZI CAROLYN R director | Common Stock | 17,769 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 12 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of OmniAb stock today?
One share of OmniAb stock can currently be purchased for approximately $2.02.
-
When is OmniAb's next earnings date?
Unfortunately, OmniAb's (OABI) next earnings date is currently unknown.
-
Does OmniAb pay dividends?
No, OmniAb does not pay dividends.
-
How much money does OmniAb make?
OmniAb has a market capitalization of 418.70M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 42.17% to 34.16M US dollars. OmniAb made a loss 50.62M US dollars in net income (profit) last year or -$0.19 on an earnings per share basis.
-
What is OmniAb's stock symbol?
OmniAb, Inc. is traded on the NASDAQ under the ticker symbol "OABI".
-
What is OmniAb's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of OmniAb?
Shares of OmniAb can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does OmniAb have?
As Jul 2024, OmniAb employs 106 workers.
-
When OmniAb went public?
OmniAb, Inc. is publicly traded company for more then 3 years since IPO on 30 Sep 2021.
-
What is OmniAb's official website?
The official website for OmniAb is omniab.com.
-
Where are OmniAb's headquarters?
OmniAb is headquartered at 5980 Horton Street, EmeryVille, CA.
-
How can i contact OmniAb?
OmniAb's mailing address is 5980 Horton Street, EmeryVille, CA and company can be reached via phone at +51 02507800.
OmniAb company profile:
OmniAb, Inc.
omniab.comExchange:
NASDAQ
Full time employees:
106
Industry:
Biotechnology
Sector:
Healthcare
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
5980 Horton Street
EmeryVille, CA 94608
EmeryVille, CA 94608
CIK: 0001846253
ISIN: US68218J1034
CUSIP: 68218J103
